Menu
GeneBe

FOXC2

forkhead box C2, the group of Forkhead boxes

Basic information

Region (hg38): 16:86566828-86569728

Previous symbols: [ "FKHL14" ]

Links

ENSG00000176692NCBI:2303OMIM:602402HGNC:3801Uniprot:Q99958AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • lymphedema-distichiasis syndrome (Definitive), mode of inheritance: AD
  • lymphedema-distichiasis syndrome (Strong), mode of inheritance: AD
  • lymphedema-distichiasis syndrome (Strong), mode of inheritance: AD
  • lymphedema-distichiasis syndrome (Supportive), mode of inheritance: AD
  • lymphedema-distichiasis syndrome (Limited), mode of inheritance: AD
  • lymphedema-distichiasis syndrome (Definitive), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Lymphedema-distichiasis syndromeADCardiovascularThe condition can involve congenital cardiac anomalies, and awareness may allow early managementCardiovascular; Dermatologic; Musculoskeletal; Ophthalmologic14269895; 3573000; 10086462; 11078474; 11499682; 11694548; 12485195; 12114478; 15523639; 17372167; 19760751; 20186799; 20301630; 20450314; 20552815; 21918810; 22349027; 22768468

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the FOXC2 gene.

  • not provided (88 variants)
  • Inborn genetic diseases (37 variants)
  • Distichiasis-lymphedema syndrome (21 variants)
  • not specified (6 variants)
  • FOXC2-related condition (5 variants)
  • Non-immune hydrops fetalis (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the FOXC2 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
24
clinvar
7
clinvar
31
missense
1
clinvar
1
clinvar
61
clinvar
7
clinvar
1
clinvar
71
nonsense
4
clinvar
5
clinvar
1
clinvar
10
start loss
0
frameshift
14
clinvar
4
clinvar
1
clinvar
19
inframe indel
3
clinvar
3
splice donor/acceptor (+/-2bp)
0
splice region
0
non coding
1
clinvar
2
clinvar
3
Total 19 10 66 32 10

Variants in FOXC2

This is a list of pathogenic ClinVar variants found in the FOXC2 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
16-86566986-G-T Benign (Jun 18, 2021)1245191
16-86567342-G-A Inborn genetic diseases Uncertain significance (Apr 12, 2022)2207974
16-86567354-G-A Uncertain significance (Sep 21, 2023)2907498
16-86567355-T-C Inborn genetic diseases Uncertain significance (Jul 25, 2023)2613985
16-86567356-G-A Likely benign (Nov 03, 2023)2807758
16-86567381-G-C Inborn genetic diseases Uncertain significance (Feb 13, 2023)2483073
16-86567404-T-C Likely benign (Aug 21, 2018)764188
16-86567415-C-T Uncertain significance (Dec 31, 2019)1311718
16-86567433-G-T Uncertain significance (Jun 01, 2023)2646947
16-86567443-C-T not specified Benign (Jan 05, 2024)259691
16-86567457-A-T Distichiasis-lymphedema syndrome Pathogenic (Jan 02, 2019)599243
16-86567459-T-G Inborn genetic diseases Uncertain significance (Aug 19, 2022)1716881
16-86567463-GC-G Pathogenic (Jun 06, 2017)449991
16-86567489-A-G Inborn genetic diseases Uncertain significance (Dec 01, 2022)2383620
16-86567496-G-A Inborn genetic diseases Uncertain significance (Nov 22, 2023)3096276
16-86567496-G-T Uncertain significance (Jul 20, 2022)2202300
16-86567504-G-T Uncertain significance (Dec 10, 2022)2819936
16-86567518-C-T Benign (Mar 14, 2023)1968923
16-86567534-C-CCT Distichiasis-lymphedema syndrome Pathogenic (Jun 01, 2001)7254
16-86567543-C-CT Distichiasis-lymphedema syndrome Pathogenic (Jun 01, 2001)7253
16-86567560-C-CAGCT Pathogenic (Oct 31, 2022)2031286
16-86567578-C-T Likely benign (Aug 30, 2023)2781961
16-86567586-C-A FOXC2-related disorder Uncertain significance (Jul 17, 2023)2631715
16-86567602-C-G Likely benign (Jun 14, 2018)750253
16-86567605-G-A Likely benign (Jun 01, 2018)707364

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
FOXC2protein_codingprotein_codingENST00000320354 11683
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.1340.84700000.00
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense-0.2512362251.050.00001073174
Missense in Polyphen93105.960.877691336
Synonymous-4.251591041.530.000005341042
Loss of Function2.0239.840.3054.27e-7131

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.000.00
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.000.00
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Transcriptional activator. Might be involved in the formation of special mesenchymal tissues. {ECO:0000269|PubMed:9169153}.;
Disease
DISEASE: Lymphedema-distichiasis (LYD) [MIM:153400]: A disorder characterized by primary limb lymphedema associated with distichiasis (double rows of eyelashes, with extra eyelashes growing from the Meibomian gland orifices). Swelling of the extremities, due to altered lymphatic flow, usually appears in late childhood or puberty. Most affected individuals have ocular findings including corneal irritation, recurrent conjunctivitis, and photophobia. Drooping of the upper eyelid (ptosis) is a variable feature of the lymphedema-distichiasis syndrome, occurring in about 30% of patients. {ECO:0000269|PubMed:11078474, ECO:0000269|PubMed:11371511, ECO:0000269|PubMed:11499682}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Heart Development;Adipogenesis;Mesodermal Commitment Pathway;BMP Signaling Pathway in Eyelid Development;EMT transition in Colorectal Cancer (Consensus)

Recessive Scores

pRec
0.238

Haploinsufficiency Scores

pHI
0.386
hipred
hipred_score
ghis
0.534

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.928

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Foxc2
Phenotype
homeostasis/metabolism phenotype; craniofacial phenotype; muscle phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; liver/biliary system phenotype; embryo phenotype; renal/urinary system phenotype; skeleton phenotype; immune system phenotype; vision/eye phenotype; digestive/alimentary phenotype; hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); pigmentation phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; respiratory system phenotype;

Gene ontology

Biological process
negative regulation of transcription by RNA polymerase II;lymphangiogenesis;regulation of transcription by RNA polymerase II;mesoderm development;heart development;insulin receptor signaling pathway;anatomical structure morphogenesis;response to hormone;positive regulation of endothelial cell migration;cell differentiation;positive regulation of cell adhesion mediated by integrin;positive regulation of vascular wound healing;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;positive regulation of cell migration involved in sprouting angiogenesis;negative regulation of cold-induced thermogenesis
Cellular component
nucleus;nucleoplasm;nuclear body
Molecular function
RNA polymerase II regulatory region sequence-specific DNA binding;RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;DNA-binding transcription factor activity;protein binding;chromatin DNA binding;identical protein binding;sequence-specific DNA binding;transcription regulatory region DNA binding;promoter-specific chromatin binding